Mark Hancock, who serves as the Co-Founder and Executive Vice Chair of PACS Group, Inc. (NASDAQ:PACS), has offloaded a substantial portion of his equity holdings. According to a Form 4 filing submitted to the Securities and Exchange Commission, Hancock sold 199,000 shares of common stock across multiple transactions on June 25 and June 26, 2026. The aggregate value of these sales reached $8,075,786. The shares were divested at prices fluctuating between $40.3255 and $41.01 per share.
This divestment activity coincides with a period of significant price appreciation for PACS Group. The stock is currently trading near its 52-week high of $43.08, having delivered a remarkable 226% return over the trailing twelve months. At the time of the reporting, PACS shares were valued at $41.89. Valuation metrics from InvestingPro suggest that the current price sits above the company's Fair Value, positioning PACS on the platform's list of most overvalued stocks.
The transactions were executed under the parameters of a Rule 10b5-1 trading plan, which Hancock established on March 11, 2026. The specific breakdown of the sales reveals a systematic approach to the divestment. On June 25, Hancock disposed of 138,069 shares at a weighted average price of $40.3255. These shares were sold in multiple transactions within a price range of $40.00 to $40.67. The following day, June 26, he sold an additional 61,731 shares at a weighted average price of $40.4964, with individual transaction prices ranging from $40.01 to $41.0016. Also on June 26, Hancock completed a separate sale of 200 shares at a price of $41.01 per share.
Following these recent transactions, Hancock's direct holdings in PACS Group common stock stand at 54,102,597 shares. The stock has shown recent volatility, with closing prices at $41.89, representing a 1.21 point increase or 2.97% gain. After-hours trading saw a slight movement to $41.90, reflecting a 0.01 point increase or 0.02% gain.
Despite the executive's share sales, PACS Group has demonstrated strong financial performance. The company reported first-quarter 2026 results that surpassed earnings expectations. The reported earnings per share (EPS) was $0.50, beating the forecasted $0.44. This represents a 13.64% positive surprise. Revenue for the quarter reached $1.42 billion, marking an 11% increase compared to the previous year.
Analyst sentiment remains constructive. Truist Securities has reiterated its Buy rating on PACS Group, setting a price target of $52.00. The firm cited the company's strong market positioning and attractive demand trends as primary drivers for their confidence. Truist also highlighted PACS Group's clinical and operational execution, alongside ongoing regulatory-focused investment activity, as key factors supporting their outlook.